Changing
Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025
capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes
X4 Pharma Halves Workforce in Second Round of 2025 Layoffs
X4 Pharmaceuticals; layoffs; restructuring; chronic neutropenia; mavorixafor; management changes; biotech
Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025
Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence
Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance
Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition
RFK Jr. Reshuffles Top Leadership at HHS, Replaces Chief of Staff and Deputy Policy Chief
RFK Jr.; HHS leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; personnel changes; Make America Healthy Again
RFK Jr. Reshuffles Top HHS Leadership, Names New Acting Chief of Staff
RFK Jr.; HHS; leadership shakeup; chief of staff; personnel changes; Matt Buckham; Heather Flick Melanson; Hannah Anderson; health policy; Department of Health and Human Services
RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS
Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
Vor Bio’s $4B+ Revival Deal for RemeGen’s Autoimmune Drug Triggers Divergent Stock Moves
Vor Bio; RemeGen; telitacicept; autoimmune disease; $4 billion deal; myasthenia gravis; stock reaction; CEO change; PIPE financing
FDA’s Top Cell and Gene Therapy Leaders Exit Amid CBER Upheaval
FDA; cell therapy; gene therapy; CBER; Nicole Verdun; Rachael Anatol; Peter Marks; leadership changes; biopharma regulation